BACKGROUND: Erythema migrans (EM) is caused primarily by Borrelia afzelii in Europe and solely by Borrelia burgdorferi in the United States. B. burgdorferi infection in the United States has previously been associated with faster expansion of EM lesions and with more associated symptoms, compared with B. afzelii infection in Europe. However, reasons for these differences are not yet known. METHODS: We determined the Borrelia species infecting 67 US or Austrian patients with EM. The clinical pictures and chemokine and cytokine mRNA levels in lesional skin were then compared in the 19 B. burgdorferi-infected US patients and the 37 B. afzelii-infected Austrian patients, the 2 largest groups. RESULTS: The 19 B. burgdorferi-infected US patients had faster-expanding EM lesions and a median of 4 associated signs and symptoms, whereas the 37 B. afzelii-infected Austrian patients had slower-expanding lesions and usually did not experience associated symptoms. Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). In addition, compared with the EM lesions of Austrian patients, the EM lesions of US patients tended to have higher mRNA levels of the macrophage-associated proinflammatory cytokines interleukin 1beta and tumor necrosis factor alpha, and they had significantly higher mRNA expression of the antiinflammatory cytokines interleukin 10 and transforming growth factor beta. CONCLUSIONS: The EM lesions of B. burgdorferi-infected US patients expanded faster, were associated with more symptoms, and had higher mRNA levels of macrophage-associated chemokines and cytokines than did the EM lesions of B. afzelii-infected Austrian patients.
BACKGROUND:Erythema migrans (EM) is caused primarily by Borrelia afzelii in Europe and solely by Borrelia burgdorferi in the United States. B. burgdorferiinfection in the United States has previously been associated with faster expansion of EM lesions and with more associated symptoms, compared with B. afzeliiinfection in Europe. However, reasons for these differences are not yet known. METHODS: We determined the Borrelia species infecting 67 US or Austrian patients with EM. The clinical pictures and chemokine and cytokine mRNA levels in lesional skin were then compared in the 19 B. burgdorferi-infected US patients and the 37 B. afzelii-infected Austrian patients, the 2 largest groups. RESULTS: The 19 B. burgdorferi-infected US patients had faster-expanding EM lesions and a median of 4 associated signs and symptoms, whereas the 37 B. afzelii-infected Austrian patients had slower-expanding lesions and usually did not experience associated symptoms. Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). In addition, compared with the EM lesions of Austrian patients, the EM lesions of US patients tended to have higher mRNA levels of the macrophage-associated proinflammatory cytokines interleukin 1beta and tumor necrosis factor alpha, and they had significantly higher mRNA expression of the antiinflammatory cytokines interleukin 10 and transforming growth factor beta. CONCLUSIONS: The EM lesions of B. burgdorferi-infected US patients expanded faster, were associated with more symptoms, and had higher mRNA levels of macrophage-associated chemokines and cytokines than did the EM lesions of B. afzelii-infected Austrian patients.
Authors: Meghan L Marre; Courtney T Darcy; Janeth Yinh; Shizuo Akira; Satoshi Uematsu; Allen C Steere; Linden T Hu Journal: Infect Immun Date: 2010-10-04 Impact factor: 3.441
Authors: Marije Oosting; Frank L van de Veerdonk; Thirumala-Devi Kanneganti; Patrick Sturm; Ineke Verschueren; Anneleen Berende; Jos W M van der Meer; Bart-Jan Kullberg; Mihai G Netea; Leo A B Joosten Journal: Eur J Immunol Date: 2010-12-09 Impact factor: 5.532
Authors: Aarti Gautam; Saurabh Dixit; Mario T Philipp; Shree R Singh; Lisa A Morici; Deepak Kaushal; Vida A Dennis Journal: Infect Immun Date: 2011-09-26 Impact factor: 3.441
Authors: Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead Journal: Nat Rev Dis Primers Date: 2016-12-15 Impact factor: 52.329
Authors: Adriana Marques; Ira Schwartz; Gary P Wormser; Yanmei Wang; Ronald L Hornung; Cumhur Y Demirkale; Peter J Munson; Siu-Ping Turk; Carla Williams; Chyi-Chia Richard Lee; Jun Yang; Mary M Petzke Journal: J Infect Dis Date: 2017-12-27 Impact factor: 5.226
Authors: Klemen Strle; Elise E Drouin; Shiqian Shen; Joseph El Khoury; Gail McHugh; Eva Ruzic-Sabljic; Franc Strle; Allen C Steere Journal: J Infect Dis Date: 2009-12-15 Impact factor: 5.226
Authors: Juan C Salazar; Star Duhnam-Ems; Carson La Vake; Adriana R Cruz; Meagan W Moore; Melissa J Caimano; Leonor Velez-Climent; Jonathan Shupe; Winfried Krueger; Justin D Radolf Journal: PLoS Pathog Date: 2009-05-22 Impact factor: 6.823